Atlas Trials

APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma

Clinical trial NCT04942067 · UNKNOWN

Trial details

NCT number
NCT04942067
Sponsor
Ascentage Pharma Group Inc.
Status
UNKNOWN
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Multiple MyelomaAmyloidosis
Start date
2021-12-23
Primary completion
2024-09-01
Enrollment
108

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.